At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionisnews2025-03-07T16:16:52+00:00March 7th, 2025|Endpoints News|
No news is good news? Merck KGaA quiet on potential SpringWorks takeovernews2025-03-06T11:58:31+00:00March 6th, 2025|Endpoints News|
Jazz to buy Chimerix for $935M to get brain tumor drug five months ahead of PDUFAnews2025-03-05T12:39:38+00:00March 5th, 2025|Endpoints News|
Acelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis mergernews2025-03-04T15:08:52+00:00March 4th, 2025|Endpoints News|
Protagonist, Takeda’s profit sharing deal under spotlight after Phase 3 blood disorder trial winnews2025-03-03T16:28:08+00:00March 3rd, 2025|Endpoints News|
Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfrontnews2025-03-03T15:57:41+00:00March 3rd, 2025|Endpoints News|
Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanismsnews2025-03-03T14:20:59+00:00March 3rd, 2025|Endpoints News|
Callio emerges with $187M and ADCs from a decade-old Singapore biotechnews2025-03-03T14:00:31+00:00March 3rd, 2025|Endpoints News|
AbbVie finally enters obesity race with $350M upfront for Gubra’s amylinnews2025-03-03T08:56:11+00:00March 3rd, 2025|Endpoints News|
